Immune Thrombocytopenia epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Created page with "__NOTOC__ {{Xyz}} {{CMG}}; {{AE}} ==Overview== ==Epidemiology and Demographics== ===Incidence=== *The incidence/prevalence of [disease name] is approximately [number range]..."
 
No edit summary
 
(2 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Xyz}}
{{Immune Thrombocytopenia}}


{{CMG}}; {{AE}}  
{{CMG}}; {{AE}} {{Maryam}}
==Overview==
==Overview==
The incidence of Immune thrombocytopenia is approximately 1.6- 3.9 per 100,000 adult  individuals worldwide and 1.1- 5.8 per 100,000 individuals among children. Patients of all age groups may develop Immune thrombocytopenia. The Prevalence of chronic Immune thrombocytopenia increases with age. Black and non-hispanic individuals are less likely to develop ITP.


==Epidemiology and Demographics==
==Epidemiology and Demographics==
===Incidence===
===Incidence===
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
 
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
*The incidence of Immune thrombocytopenia is approximately 1.6- 3.9 per 100,000 adult  individuals worldwide and 1.1- 5.8 per 100,000 individuals among children. The overall incidence rate was higher in women (4.4 per 100,000 person year) than men ( 3.4 per 100,000 person year).Women are more commonly affected by Immune thrombocytopenia than men.
*In year 2014, the incidence of Immune thrombocytopenia among French people is approximately 2.9/ 100,000 person years with higher incidence among women. The incidence has bimodal distribution with first peak among male children among 1-5 years and men over 75 years of age. However the distribution for women is constant.<ref name="KohliChaturvedi20193">{{cite journal|last1=Kohli|first1=Rahil|last2=Chaturvedi|first2=Shruti|title=Epidemiology and Clinical Manifestations of Immune Thrombocytopenia|journal=Hämostaseologie|volume=39|issue=03|year=2019|pages=238–249|issn=0720-9355|doi=10.1055/s-0039-1683416}}</ref> <ref name="pmidhttps://doi.org/10.1182/blood-2014-05-578336">{{cite journal| author=Schmoldt A, Benthe HF, Haberland G| title=Digitoxin metabolism by rat liver microsomes. | journal=Biochem Pharmacol | year= 1975 | volume= 24 | issue= 17 | pages= 1639-41 | pmid=https://doi.org/10.1182/blood-2014-05-578336 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10  }}</ref>


===Prevalence===
===Prevalence===
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
 
*The prevalence of chronic immune thrombocytopenia ( lasting longer than 12 months) is approximately 9.5-11.2 per 100,000 individuals in the United States.
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
*The prevalence of [disease/malignancy] is estimated to be [number] cases annually.
*The prevalence of [disease/malignancy] is estimated to be [number] cases annually.


===Case-fatality rate/Mortality rate===
===Case-fatality rate/Mortality rate===
*In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
*In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
*The case-fatality rate/mortality rate of [disease name] is approximately [number range].
*The case-fatality rate/mortality rate of [disease name] is approximately [number range].


===Age===
===Age===
*Patients of all age groups may develop [disease name].
 
*The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
*Patients of all age groups may develop Immune thrombocytopenia.
*[Disease name] commonly affects individuals younger than/older than [number of years] years of age.  
*The Prevalence of chronic Immune thrombocytopenia increases with age; the childhood ITP remits spontaneously.
*Immune thrombocytopenia commonly affects individuals younger than 5 years of age.
*[Chronic disease name] is usually first diagnosed among [age group].
*[Chronic disease name] is usually first diagnosed among [age group].
*[Acute disease name] commonly affects [age group].
*[Acute disease name] commonly affects [age group].


===Race===
===Race===
*There is no racial predilection to [disease name].
*There is no racial predilection to [disease name].
*[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
*Black and non-hispanic individuals are less likely to develop ITP, thereafter, the providers should suspect alternative diagnosis or secondary ITP in these races.<ref name="KimGrimes2020">{{cite journal|last1=Kim|first1=Taylor Olmsted|last2=Grimes|first2=Amanda B.|last3=Kirk|first3=Susan E.|last4=Gilbert|first4=Megan M.|last5=Reed|first5=Helen D.|last6=Staggers|first6=Kristen A.|last7=Walker|first7=Lauryn A.|last8=Arulselvan|first8=Abinaya|last9=Cohen|first9=A. Sarah|last10=Lambert|first10=Michele P.|last11=Despotovic|first11=Jenny M.|title=Racial variation in ITP prevalence and chronic disease phenotype suggests biological differences|journal=Blood|volume=136|issue=5|year=2020|pages=640–643|issn=0006-4971|doi=10.1182/blood.2020004888}}</ref>
 
===Gender===
===Gender===
*[Disease name] affects men and women equally.
*[Disease name] affects men and women equally.
*[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
*Women are more commonly affected by Immune thrombocytopenia than men.
 
===Season===


===Region===
*The majority of Immune thrombocytopenia cases are reported in January and the minority in summer in all age group probably due to viral infection..<ref name="KohliChaturvedi20193" /> <ref name="pmidhttps://doi.org/10.1182/blood-2014-05-578336" />
*The majority of [disease name] cases are reported in [geographical region].


*[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
*[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].

Latest revision as of 17:55, 8 February 2021

Immune Thrombocytopenia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Immune Thrombocytopenia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Immune Thrombocytopenia epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Immune Thrombocytopenia epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Immune Thrombocytopenia epidemiology and demographics

CDC on Immune Thrombocytopenia epidemiology and demographics

Immune Thrombocytopenia epidemiology and demographics in the news

Blogs on Immune Thrombocytopenia epidemiology and demographics

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Immune Thrombocytopenia epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maryam Barkhordarian, M.D.[2]

Overview

The incidence of Immune thrombocytopenia is approximately 1.6- 3.9 per 100,000 adult individuals worldwide and 1.1- 5.8 per 100,000 individuals among children. Patients of all age groups may develop Immune thrombocytopenia. The Prevalence of chronic Immune thrombocytopenia increases with age. Black and non-hispanic individuals are less likely to develop ITP.

Epidemiology and Demographics

Incidence

  • The incidence of Immune thrombocytopenia is approximately 1.6- 3.9 per 100,000 adult individuals worldwide and 1.1- 5.8 per 100,000 individuals among children. The overall incidence rate was higher in women (4.4 per 100,000 person year) than men ( 3.4 per 100,000 person year).Women are more commonly affected by Immune thrombocytopenia than men.
  • In year 2014, the incidence of Immune thrombocytopenia among French people is approximately 2.9/ 100,000 person years with higher incidence among women. The incidence has bimodal distribution with first peak among male children among 1-5 years and men over 75 years of age. However the distribution for women is constant.[1] [2]

Prevalence

  • The prevalence of chronic immune thrombocytopenia ( lasting longer than 12 months) is approximately 9.5-11.2 per 100,000 individuals in the United States.
  • In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
  • The prevalence of [disease/malignancy] is estimated to be [number] cases annually.

Case-fatality rate/Mortality rate

  • In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
  • The case-fatality rate/mortality rate of [disease name] is approximately [number range].

Age

  • Patients of all age groups may develop Immune thrombocytopenia.
  • The Prevalence of chronic Immune thrombocytopenia increases with age; the childhood ITP remits spontaneously.
  • Immune thrombocytopenia commonly affects individuals younger than 5 years of age.
  • [Chronic disease name] is usually first diagnosed among [age group].
  • [Acute disease name] commonly affects [age group].

Race

  • There is no racial predilection to [disease name].
  • Black and non-hispanic individuals are less likely to develop ITP, thereafter, the providers should suspect alternative diagnosis or secondary ITP in these races.[3]

Gender

  • [Disease name] affects men and women equally.
  • Women are more commonly affected by Immune thrombocytopenia than men.

Season

  • The majority of Immune thrombocytopenia cases are reported in January and the minority in summer in all age group probably due to viral infection..[1] [2]
  • [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].

Developed Countries

Developing Countries

References

  1. ↑ 1.0 1.1 Kohli, Rahil; Chaturvedi, Shruti (2019). "Epidemiology and Clinical Manifestations of Immune Thrombocytopenia". Hämostaseologie. 39 (03): 238–249. doi:10.1055/s-0039-1683416. ISSN 0720-9355.
  2. ↑ 2.0 2.1 Schmoldt A, Benthe HF, Haberland G (1975). "Digitoxin metabolism by rat liver microsomes" Check |url= value (help). Biochem Pharmacol. 24 (17): 1639–41. PMID https://doi.org/10.1182/blood-2014-05-578336 Check |pmid= value (help).
  3. ↑ Kim, Taylor Olmsted; Grimes, Amanda B.; Kirk, Susan E.; Gilbert, Megan M.; Reed, Helen D.; Staggers, Kristen A.; Walker, Lauryn A.; Arulselvan, Abinaya; Cohen, A. Sarah; Lambert, Michele P.; Despotovic, Jenny M. (2020). "Racial variation in ITP prevalence and chronic disease phenotype suggests biological differences". Blood. 136 (5): 640–643. doi:10.1182/blood.2020004888. ISSN 0006-4971.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Immune_Thrombocytopenia_epidemiology_and_demographics&oldid=1689147"